Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options

Nik Krajnc
Thomas Berger
Gabriel Bsteh

September 2021

Disability in multiple sclerosis accrues predominantly in the progressive forms of the disease. Whil...

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.

Cree, Bruce Ac
Magnusson, Baldur
Rouyrre, Nicolas
Fox, Robert J
Giovannoni, Gavin
Vermersch, Patrick
Bar-Or, Amit
Gold, Ralf
Piani Meier, Daniela
Karlsson, Göril
Tomic, Davorka
Wolf, Christian
Dahlke, Frank
Kappos, Ludwig

September 2021

BackgroundIn multiple sclerosis, impact of treatment on disability progression can be confounded if ...

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Kalincik, Tomas
Diouf, Ibrahima
Sharmin, Sifat
Malpas, Charles
Spelman, Tim
Horakova, Dana
Havrdova, Eva Kubala
Trojano, Maria
Izquierdo, Guillermo
Lugaresi, Alessandra
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Grammond, Pierre
Jokubaitis, Vilija
van der Walt, Anneke
Grand'Maison, Francois
Sola, Patrizia
Ferraro, Diana
Shaygannejad, Vahid
Alroughani, Raed
Hupperts, Raymond
Terzi, Murat
Boz, Cavit
Lechner-Scott, Jeannette
Pucci, Eugenio
Van Pesch, Vincent
Granella, Franco
Bergamaschi, Roberto
Spitaleri, Daniele
Slee, Mark
Vucic, Steve
Ampapa, Radek
McCombe, Pamela
Ramo-Tello, Cristina
Prevost, Julie
Olascoaga, Javier
Cristiano, Edgardo
Barnett, Michael
Saladino, Maria Laura
Sanchez-Menoyo, Jose Luis
Hodgkinson, Suzanne
Rozsa, Csilla
Hughes, Stella
Moore, Fraser
Shaw, Cameron
Butler, Ernest
Skibina, Olga
Gray, Orla
Kermode, Allan
Csepany, Tunde
Singhal, Bhim
Shuey, Neil
Piroska, Imre
Taylor, Bruce
Simo, Magdolna
Sirbu, Carmen-Adella
Sas, Attila
Butzkueven, Helmut

January 2021

OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remi...

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.

Christian Röver
Richard Nicholas
Sebastian Straube
Tim Friede

Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression

Röver Christian
Nicholas Richard
Straube Sebastian
Friede Tim

September 2015

Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Tsivgoulis Georgios
Katsanos Aristeidis H.
Grigoriadis Nikolaos
Hadjigeorgiou Georgios M.
Heliopoulos Ioannis
Papathanasopoulos Panagiotis
Kilidireas Constantinos
Voumvourakis Konstantinos
Dardiotis Efthimios

December 2015

A number of officially approved disease-modifying drugs (DMD) are currently available for the early ...

LEADING ARTICLE Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis

Heinz Wiendl
Sven G. Meuth

January 2015

The Author(s) 2015. This article is published with open access at Springerlink.com Abstract In indiv...

Disability as an outcome in MS clinical trials.

Ebers, GC
Heigenhauser, L
Daumer, M
Lederer, C
Noseworthy, JH

August 2008

BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been bas...

Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis receiving disease modifying therapy compared and those receiving placebo.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)

March 2015

<p>Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis r...

Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis

Lizak N.
Malpas C. B.
Sharmin S.
Havrdova E. K.
Horakova D.
Izquierdo G.
Eichau S.
Lugaresi A.
Duquette P.
Girard M.
Prat A.
Larochelle C.
Trojano M.
Grand'Maison F.
Grammond P.
Sola P.
Ferraro D.
Hupperts R.
Bergamaschi R.
Boz C.
Van Pesch V.
Spitaleri D.
Terzi M.
Kalincik T.

January 2020

Importance: It is unclear whether relapses and disease-modifying therapies are associated with the r...

MSJ794063_supplementary_material – Supplemental material for Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials

Richard S Nicholas (5685302)
Erika Han (5685305)
Joel Raffel (3148509)
Jeremy Chataway (704939)
Tim Friede (690576)

August 2018

Supplemental material, MSJ794063_supplementary_material for Over three decades study populations in ...

Disease evolution in multiple sclerosis

Ebers, G

January 2006

Multiple sclerosis is a long-term disease that evolves over a period of 30 to 40 years with progress...

Effect of disease modifying therapy on disability in Relapsing-Remitting multiple sclerosis over 15 Years

Kalincik, T.
Diouf, I.
Sharmin, S.
Malpas, C.
Spelman, T.
Horakova, D.
Havrdova, E.K.
Trojano, M.
Izquierdo, G.
Lugaresi, A.
Prat, A.
Girard, M.
Duquette, P.
Grammond, P.
Jokubaitis, V.
Van der Walt, A.
Grand'Maison, F.
Sola, P.
Ferraro, D.
Shaygannejad, V.
Alroughani, R.
Hupperts, R.
Terzi, M.
Boz, C.
Lechner-Scott, J.
Pucci, E.
van Pesch, V.
Granella, F.
Bergamaschi, R.
Spitaleri, D.
Slee, M.
Vucic, S.
Ampapa, R.
McCombe, P.
Ramo-Tello, C.
Prevost, J.
Olascoaga, J.
Cristiano, E.
Barnett, M.
Saladino, M.L.
Sanchez-Menoyo, J.L.
Hodgkinson, S.
Rózsa, C.
Hughes, S.
Moore, F.
Shaw, C.
Butler, E.
Skibina, O.
Gray, O.
Kermode, A.
Csepany, T.
Singhal, B.
Shuey, N.
Piroska, I.
Taylor, B.
Simon, M.
Sirbu, C-A
Sas, A.
Butzkueven, H.

January 2020

Objective To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remit...

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

Lizak, Nathaniel
Malpas, Charles B
Sharmin, Sifat
Havrdova, Eva Kubala
Horakova, Dana
Izquierdo, Guillermo
Eichau, Sara
Lugaresi, Alessandra
Duquette, Pierre
Girard, Marc
Prat, Alexandre
Larochelle, Catherine
Trojano, Maria
Grand'Maison, Francois
Grammond, Pierre
Sola, Patrizia
Ferraro, Diana
Hupperts, Raymond
Bergamaschi, Roberto
Boz, Cavit
van Pesch, Vincent
Spitaleri, Daniele
Terzi, Murat
Kalincik, Tomas
MSBase Study Group

January 2020

It is unclear whether relapses and disease-modifying therapies are associated with the rate of disab...

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

Lavery, Amy M.
Verhey, Leonard H.
Waldman, Amy T.

February 2018

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as ac...

Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options

Nik Krajnc
Thomas Berger
Gabriel Bsteh

September 2021

Disability in multiple sclerosis accrues predominantly in the progressive forms of the disease. Whil...

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.

Cree, Bruce Ac
Magnusson, Baldur
Rouyrre, Nicolas
Fox, Robert J
Giovannoni, Gavin
Vermersch, Patrick
Bar-Or, Amit
Gold, Ralf
Piani Meier, Daniela
Karlsson, Göril
Tomic, Davorka
Wolf, Christian
Dahlke, Frank
Kappos, Ludwig

September 2021

BackgroundIn multiple sclerosis, impact of treatment on disability progression can be confounded if ...

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Kalincik, Tomas
Diouf, Ibrahima
Sharmin, Sifat
Malpas, Charles
Spelman, Tim
Horakova, Dana
Havrdova, Eva Kubala
Trojano, Maria
Izquierdo, Guillermo
Lugaresi, Alessandra
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Grammond, Pierre
Jokubaitis, Vilija
van der Walt, Anneke
Grand'Maison, Francois
Sola, Patrizia
Ferraro, Diana
Shaygannejad, Vahid
Alroughani, Raed
Hupperts, Raymond
Terzi, Murat
Boz, Cavit
Lechner-Scott, Jeannette
Pucci, Eugenio
Van Pesch, Vincent
Granella, Franco
Bergamaschi, Roberto
Spitaleri, Daniele
Slee, Mark
Vucic, Steve
Ampapa, Radek
McCombe, Pamela
Ramo-Tello, Cristina
Prevost, Julie
Olascoaga, Javier
Cristiano, Edgardo
Barnett, Michael
Saladino, Maria Laura
Sanchez-Menoyo, Jose Luis
Hodgkinson, Suzanne
Rozsa, Csilla
Hughes, Stella
Moore, Fraser
Shaw, Cameron
Butler, Ernest
Skibina, Olga
Gray, Orla
Kermode, Allan
Csepany, Tunde
Singhal, Bhim
Shuey, Neil
Piroska, Imre
Taylor, Bruce
Simo, Magdolna
Sirbu, Carmen-Adella
Sas, Attila
Butzkueven, Helmut

January 2021

OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remi...

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.

Christian Röver
Richard Nicholas
Sebastian Straube
Tim Friede

Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression

Röver Christian
Nicholas Richard
Straube Sebastian
Friede Tim

September 2015

Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Tsivgoulis Georgios
Katsanos Aristeidis H.
Grigoriadis Nikolaos
Hadjigeorgiou Georgios M.
Heliopoulos Ioannis
Papathanasopoulos Panagiotis
Kilidireas Constantinos
Voumvourakis Konstantinos
Dardiotis Efthimios

December 2015

A number of officially approved disease-modifying drugs (DMD) are currently available for the early ...

LEADING ARTICLE Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis

Heinz Wiendl
Sven G. Meuth

January 2015

The Author(s) 2015. This article is published with open access at Springerlink.com Abstract In indiv...

Disability as an outcome in MS clinical trials.

Ebers, GC
Heigenhauser, L
Daumer, M
Lederer, C
Noseworthy, JH

August 2008

BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been bas...

Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis receiving disease modifying therapy compared and those receiving placebo.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)

March 2015

<p>Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis r...

Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis

Lizak N.
Malpas C. B.
Sharmin S.
Havrdova E. K.
Horakova D.
Izquierdo G.
Eichau S.
Lugaresi A.
Duquette P.
Girard M.
Prat A.
Larochelle C.
Trojano M.
Grand'Maison F.
Grammond P.
Sola P.
Ferraro D.
Hupperts R.
Bergamaschi R.
Boz C.
Van Pesch V.
Spitaleri D.
Terzi M.
Kalincik T.

January 2020

Importance: It is unclear whether relapses and disease-modifying therapies are associated with the r...

MSJ794063_supplementary_material – Supplemental material for Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials

Richard S Nicholas (5685302)
Erika Han (5685305)
Joel Raffel (3148509)
Jeremy Chataway (704939)
Tim Friede (690576)

August 2018

Supplemental material, MSJ794063_supplementary_material for Over three decades study populations in ...

Disease evolution in multiple sclerosis

Ebers, G

January 2006

Multiple sclerosis is a long-term disease that evolves over a period of 30 to 40 years with progress...

Effect of disease modifying therapy on disability in Relapsing-Remitting multiple sclerosis over 15 Years

Kalincik, T.
Diouf, I.
Sharmin, S.
Malpas, C.
Spelman, T.
Horakova, D.
Havrdova, E.K.
Trojano, M.
Izquierdo, G.
Lugaresi, A.
Prat, A.
Girard, M.
Duquette, P.
Grammond, P.
Jokubaitis, V.
Van der Walt, A.
Grand'Maison, F.
Sola, P.
Ferraro, D.
Shaygannejad, V.
Alroughani, R.
Hupperts, R.
Terzi, M.
Boz, C.
Lechner-Scott, J.
Pucci, E.
van Pesch, V.
Granella, F.
Bergamaschi, R.
Spitaleri, D.
Slee, M.
Vucic, S.
Ampapa, R.
McCombe, P.
Ramo-Tello, C.
Prevost, J.
Olascoaga, J.
Cristiano, E.
Barnett, M.
Saladino, M.L.
Sanchez-Menoyo, J.L.
Hodgkinson, S.
Rózsa, C.
Hughes, S.
Moore, F.
Shaw, C.
Butler, E.
Skibina, O.
Gray, O.
Kermode, A.
Csepany, T.
Singhal, B.
Shuey, N.
Piroska, I.
Taylor, B.
Simon, M.
Sirbu, C-A
Sas, A.
Butzkueven, H.

January 2020

Objective To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remit...

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

Lizak, Nathaniel
Malpas, Charles B
Sharmin, Sifat
Havrdova, Eva Kubala
Horakova, Dana
Izquierdo, Guillermo
Eichau, Sara
Lugaresi, Alessandra
Duquette, Pierre
Girard, Marc
Prat, Alexandre
Larochelle, Catherine
Trojano, Maria
Grand'Maison, Francois
Grammond, Pierre
Sola, Patrizia
Ferraro, Diana
Hupperts, Raymond
Bergamaschi, Roberto
Boz, Cavit
van Pesch, Vincent
Spitaleri, Daniele
Terzi, Murat
Kalincik, Tomas
MSBase Study Group

January 2020

It is unclear whether relapses and disease-modifying therapies are associated with the rate of disab...

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

Lavery, Amy M.
Verhey, Leonard H.
Waldman, Amy T.

February 2018

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as ac...

Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options

Nik Krajnc
Thomas Berger
Gabriel Bsteh

September 2021

Disability in multiple sclerosis accrues predominantly in the progressive forms of the disease. Whil...

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.

Cree, Bruce Ac
Magnusson, Baldur
Rouyrre, Nicolas
Fox, Robert J
Giovannoni, Gavin
Vermersch, Patrick
Bar-Or, Amit
Gold, Ralf
Piani Meier, Daniela
Karlsson, Göril
Tomic, Davorka
Wolf, Christian
Dahlke, Frank
Kappos, Ludwig

September 2021

BackgroundIn multiple sclerosis, impact of treatment on disability progression can be confounded if ...

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Kalincik, Tomas
Diouf, Ibrahima
Sharmin, Sifat
Malpas, Charles
Spelman, Tim
Horakova, Dana
Havrdova, Eva Kubala
Trojano, Maria
Izquierdo, Guillermo
Lugaresi, Alessandra
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Grammond, Pierre
Jokubaitis, Vilija
van der Walt, Anneke
Grand'Maison, Francois
Sola, Patrizia
Ferraro, Diana
Shaygannejad, Vahid
Alroughani, Raed
Hupperts, Raymond
Terzi, Murat
Boz, Cavit
Lechner-Scott, Jeannette
Pucci, Eugenio
Van Pesch, Vincent
Granella, Franco
Bergamaschi, Roberto
Spitaleri, Daniele
Slee, Mark
Vucic, Steve
Ampapa, Radek
McCombe, Pamela
Ramo-Tello, Cristina
Prevost, Julie
Olascoaga, Javier
Cristiano, Edgardo
Barnett, Michael
Saladino, Maria Laura
Sanchez-Menoyo, Jose Luis
Hodgkinson, Suzanne
Rozsa, Csilla
Hughes, Stella
Moore, Fraser
Shaw, Cameron
Butler, Ernest
Skibina, Olga
Gray, Orla
Kermode, Allan
Csepany, Tunde
Singhal, Bhim
Shuey, Neil
Piroska, Imre
Taylor, Bruce
Simo, Magdolna
Sirbu, Carmen-Adella
Sas, Attila
Butzkueven, Helmut

January 2021

OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remi...

Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

Abstract

Extracted data

Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

Abstract

Extracted data

Related items

Related items